ClinicalTrials.gg
Not yet recruitingNCT07733427PITUpdated Sep 10, 2026

Evaluating the Effectiveness of AIT in the Treatment of Pain Related to Pancreatic Cancer

An interventional study of Intrathecal catheter connected to an implantable pump and Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections in Pancreatic Cancer Pain, Intrathecal Analgesic and Intrathecal Administration of the Drug, sponsored by Clinique Bizet. Not yet recruiting at 3 sites in France. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Clinique Bizet · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 234 studies in Pancreatic Neoplasms with a site in France — 52 open to participants now, 74 under way, 11 of them phase 3. Pancreatic Neoplasms · France.

Planned enrollment
146th of 181
40 · median 150
Started
2026
with 11 others
No phase
44 of 234
16 open now
Primary completion
2027-03
later than 28 of 73 live
Registered
232nd of 234
by date

Among the 234 studies in Pancreatic Neoplasms with a site in France, this one is the 146th largest by planned enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2026, is one of 44 with no phase, reaches primary completion later than 28 of the 73 other live ones, and was the 232nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

52 of the 234 studies in Pancreatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Pancreatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

The aim of this clinical trial is to assess the effectiveness of intratracheal analgesia on pain intensity in cancer patients, from the start of treatment up to 3 months. It will also investigate the safety of this technique. The main questions it seeks to answer are as follows:

What is the impact on the use of opioid analgesics, and can this be measured? What is the quality of life? What is the quality of sleep, and can this be assessed? How does the patient's weight change? Is the patient satisfied? What is the patient's overall survival?

The researchers will assess the equivalent daily dose of morphine (mg/day) between enrolment and follow-up visits, as well as the number of patients requiring an escalation of analgesic treatment. Overall quality of life score measured using the ESAS questionnaire between enrolment and follow-up visits; satisfaction assessed using a numerical satisfaction scale (0-10); sleep quality assessed using the ISI questionnaire; and the tolerability and safety of the technique assessed by monitoring adverse events.

Eligible participants:

Following implantation of the intrathecal pump, participants will have scheduled consultations at day 30, then at 3, 6, 9 and 12 months, with questionnaires to be completed.

03

Conditions studied

  • Pancreatic Cancer Pain
  • Intrathecal Analgesic
  • Intrathecal Administration of the Drug
  • Pancreatic Carcinoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject aged over 20 years

  • Patient with confirmed pancreatic carcinoma
  • Chronic cancer-related pain that is inadequately controlled by standard treatment or for whom analgesics are .
  • EMO \< 120 mg/day Patients experiencing side effects: sedation, vomiting, constipation, or an allergy to morphine.
  • Signed
  • Participants affiliated with or eligible for a social security scheme
  • Agree to complete the various study questionnaires

Exclusion criteria

Exclusion Criteria:

Patients under the age of 20.

  • to intratracheal analgesia
  • Acute respiratory infection
  • Uncontrolled coagulation disorder
  • Pregnancy or breastfeeding
  • Unable to comply with medical follow-up for the study.
  • Adults who are legally protected, under guardianship or under a conservatorship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intrathecal catheter implantable pump

    Administration of the medicine via an intrathecal catheter connected to an implantable pump

    Device: Intrathecal catheter connected to an implantable pump · Drug: Administration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections

Interventions

  • DeviceIntrathecal catheter connected to an implantable pump

    Epidural puncture (AL injection), followed by a lumbar puncture and collection of cerebrospinal fluid. Positioning of the catheter behind the spinal cord at the desired metameric level for the pancreas (T5-T7), and positioning of the pump in the flank or buttock.

  • DrugAdministration of medication, including analgesics, via an intrathecal catheter connected to an implantable pump or via periodic injections

    Medications are administered via an intrathecal catheter connected to an implantable pump or via periodic injections; the patient is admitted to hospital with morphine (IV, PO, transdermal) discontinued on entry to the unit (the same applies to methadone). Depending on the condition of the patient's abdominal skin (stoma, multiple injections, etc.) and any foreseeable technical difficulties during MRI scanning (in the left or right lateral positions), the procedure is performed under fluoroscopy, with appropriate antibiotic prophylaxis, under local anaesthesia, epidural anaesthesia and light sedation. Product used, dosage and frequency: Opioids: μ and δ receptors: Morphine sulphate: 50 mg/ml Ca++ channels: ziconotide: initial dose 0.5 µg/day Sodium channels: 1% ropivacaine As with a patient-controlled analgesia (PCA) system: Continuous infusion + bolus or sequential boluses Patient education on the use of the pump during their hospital stay.

06

What researchers measure

Primary outcomes

  1. Change in Edmonton Symptom Assessment System (ESAS) - Pain Subscore

    Change in pain intensity score measured by the ESAS subscale from baseline to follow-up visits. Unit of Measure: Score on a scale (0 to 10) Scale Range (Minimum and Maximum Values): 0 to 10 Direction of Scores: Higher scores mean a worse outcome (greater pain intensity).

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

Secondary outcomes

  1. Change in Edmonton Symptom Assessment System (ESAS) Overall Quality of Life Score

    Change in overall score as measured by the Edmonton Symptom Assessment System (ESAS) from baseline to follow-up visits. Unit of Measure: Score on a scale (ESAS Score) Scale Range (Minimum and Maximum Values): 0 to 10 Direction of Scores: Higher scores mean a worse outcome (greater pain intensity).

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  2. Proportion of Patients Requiring Pain Treatment Escalation

    Number of patients requiring an increase or escalation in pain management treatment during follow-up. Unit of Measure: Number of participants (or Percentage)

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  3. Change in Daily Morphine Equivalent Dose (MED)

    Change in daily opioid dose from baseline to follow-up visits. Unit of Measure: mg/day

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  4. Change in Sleep Quality Score Insomnia Severity Index (ISI)

    Change in insomnia severity measured by the Insomnia Severity Index (ISI) questionnaire from baseline to follow-up visits. Scale Range (Minimum and Maximum Values): 0 to 28 (Derived from summing the 7 individual items, each scored on a 0 to 4 scale evaluating sleep onset, maintenance, early morning awakening, satisfaction, daytime interference, noticeability, and distress) Direction of Scores: Higher score 4 means a worse outcome (greater insomnia severity and impaired quality of life) Unit of Measure: Score on a scale (ISI Score)

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  5. Change in Body Weight

    Change in body weight from baseline to follow-up visits. Unit of Measure: Kilograms (kg)

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  6. Patient Satisfaction Clinical Global Impressions Scale (typically either CGI-Severity or CGI-Improvement)

    Overall patient satisfaction Clinical Global Impressions (typically either CGI-Severity or CGI-Improvement) rated on a numerical scale. Unit of Measure: Score on a scale Scale Range (Minimum and Maximum Values): 1 to 7 Direction of Scores: Higher scores mean a worse outcome (e.g., greater illness severity or worsening condition).

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  7. Incidence of Adverse Events Related to Intratracheal Analgesia

    Number of participants experiencing at least one adverse event related to the intratracheal analgesia technique. Unit of Measure: Number of participants

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

  8. Incidence of Serious Adverse Events (SAEs)

    Number of participants experiencing a serious adverse event during the study period. Unit of Measure: Number of participants

    Time frame: Telephone call between Week 1 and Week 12, and questionnaires at Day 30, 3 months, 6 months, 9 months and 12 months

07

Study locations

3 sites
08

References and documents

Publications

  • Park J, Park EY, Han SS, Park HM, Lee M, Lee SA, Kim SW, Kim DH, Park SJ. Randomized controlled study comparing the analgesic effects of intravenous patient-controlled analgesia and patient-controlled epidural analgesia after open major surgery for pancreatobiliary cancer. HPB (Oxford). 2022 Aug;24(8):1238-1244. doi: 10.1016/j.hpb.2022.01.013. Epub 2022 Feb 3. PubMed 35183448 ↗
  • Bruel BM, Burton AW. Intrathecal Therapy for Cancer-Related Pain. Pain Med. 2016 Dec;17(12):2404-2421. doi: 10.1093/pm/pnw060. Epub 2016 Apr 28. PubMed 28025375 ↗
  • Cohen SP, Dragovich A. Intrathecal analgesia. Anesthesiol Clin. 2007 Dec;25(4):863-82, viii. doi: 10.1016/j.anclin.2007.07.001. PubMed 18054150 ↗
  • Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H. Intrathecal drug delivery. Pain Physician. 2008 Mar;11(2 Suppl):S89-S104. PubMed 18443642 ↗
  • Rizvi S, Kumar K. History and present state of targeted intrathecal drug delivery. Curr Pain Headache Rep. 2015;19(2):474. doi: 10.1007/s11916-014-0474-8. PubMed 25638694 ↗
  • Kroenke K, Theobald D, Wu J, Loza JK, Carpenter JS, Tu W. L'association de la dépression et de la douleur avec la qualité de vie liée à la santé, le handicap et l'utilisation des soins de santé chez les patients atteints de cancer. J gestion des symptômes de douleur. 2010; 40(3):327-41. [DOI] [Article gratuit PMC] [PubMed] [Google Scholar][Liste des références]
  • -Roberto A, Greco MT, Uggeri S, Cavuto S, Deandrea S, Corli O, et al. Revue systématique vivante pour évaluer le sous-traitement analgésique chez les patients atteints de cancer. Pratique de la douleur. 2022; 22(4):487-96. [DOI] [PubMed] [Google Scholar][Liste de références]
  • Haan S, Kortylewski M, Behrmann I, Muller-Esterl W, Heinrich PC, Schaper F. Cytoplasmic STAT proteins associate prior to activation. Biochem J. 2000 Feb 1;345 Pt 3(Pt 3):417-21. PubMed 10642496 ↗
  • Carvajal G, Dupoiron D, Seegers V, Lebrec N, Bore F, Dubois PY, Leblanc D, Delorme T, Jubier-Hamon S. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center. Anesth Analg. 2018 Jun;126(6):2038-2046. doi: 10.1213/ANE.0000000000002903. PubMed 29543644 ↗
  • Bruera E, Kim HN. Cancer pain. JAMA. 2003 Nov 12;290(18):2476-9. doi: 10.1001/jama.290.18.2476. No abstract available. PubMed 14612485 ↗
  • Caraceni A, Portenoy RK; a working group of the IASP Task Force on Cancer Pain. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999 Sep;82(3):263-274. doi: 10.1016/S0304-3959(99)00073-1. PubMed 10488677 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 6 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 29, 2026
StartEst.
Sep 2026
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07733427
Lead sponsor
Clinique Bizet
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Bouchra BENKESSOU Chef de projet Recherche Clinique
Contact
b.benkessou@hexagone-sante-paris.fr
+33 7 64 48 60 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion